On September 9, HANSOH PHARMA fell 3.1% in regular trading, trading at HK$34.94/share, with turnover of HK$252 million. The decline came amid broad-based weakness across the pharmaceutical sector, with major peers CSPC Pharmaceutical down 4.83%, Sino Biopharm down 4.02%, and Hengrui Pharma down 1.25%.

No company-specific negative catalyst was identified. The pullback follows a strong post-earnings rally of 16% on August 27, after the company reported first-half revenue of RMB 8.304 billion, up 11.7% year-over-year, and net profit of RMB 4.258 billion, up 35.8%. Innovative drug revenue reached a record 85.4% of total sales. Recent positive developments include NMPA acceptance of the biologics license application for HS-20093, a B7-H3-targeted ADC for small cell lung cancer, on September 2, and a full-cycle strategic partnership with National Pharmaceutical Holdings announced on September 8. Multiple investment banks have reiterated bullish ratings, with target prices ranging from HK$43.7 to HK$52.7.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)